Abstract: The present invention relates to methods of treating myocardial depression or increasing adrenergic signalling responsiveness in a subject. The methods involve administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more compounds of formula (II), for example one or more compounds of formula (I), described herein. The present invention is also concerned with compositions comprising cholesterol and/or one or more phytosterols for use in methods of treating myocardial depression or increasing adrenergic signalling responsiveness in a subject.

Abstract: The invention relates to a nanostructured delivery system comprising at least one polymer and/or at least one lipid and at least one polymethine dye, wherein the at least one polymethine dye acting as a targeting unit brings about the targeted transport of the nanostructured delivery system into a target issue. The invention also relates to a pharmaceutical composition and the uses of the nanostructured delivery system for transporting said system and, optionally, a pharmaceutical active ingredient into the target tissue, as well for treating liver and/or kidney diseases.

Abstract: The invention relates to a nanostructured delivery system comprising at least one polymer and/or at least one lipid and at least one polymethine dye, wherein the at least one polymethine dye acting as a targeting unit brings about the targeted transport of the nanostructured delivery system into a target issue. The invention also relates to a pharmaceutical composition and the uses of the nanostructured delivery system for transporting said system and, optionally, a pharmaceutical active ingredient into the target tissue, as well for treating liver and/or kidney diseases.